OncLive

OncLive
Share

OncLive

 •  October 27, 2017

The FDA has approved intravenous (IV) rolapitant (Varubi) for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting (CINV) in adults, according to TESARO, the manufacturer of the agent. Delayed nausea and vomiting occurs between 25 and 120 hours after chemotherapy. The FDA previously approved oral...

OncLive

 •  September 22, 2017

Surgical procedures and the administration of chemotherapy by central venous catheter can increase the risk of a thromboembolic events in patients with cancer. To curb this risk, anticoagulants are used in both adults and children undergoing treatment. Generally, day-to-day traumas that result in bleeding are more likely to occur in children than...

OncLive

 •  March 20, 2016

Treatment with trabectedin (Yondelis) significantly improved progression-free survival (PFS) compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial presented at the 2016 Society of Gynecologic Oncology Annual Meeting. Patients with uterine leiomyosarcoma who received...

OncLive

 •  March 20, 2016

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib (Imbruvica) in previously treated patients with chronic lymphocytic leukemia (CLL), including those with high-risk gene mutations and prognostic features, according to a poster presented at the 2016 International Congress on Hematologic Malignancies. In the...

OncLive

 •  March 15, 2016

Insights From:Stefan Faderl, MD, John Theurer Cancer Center; Raoul Tibes, MD, PhD, May Clinic; Bijal D. Shah, MD, Moffitt Cancer Center Transcript: Risk stratification in acute lymphoblastic leukemia (ALL) is absolutely the next most important thing we can do to improve outcomes. Now, risk stratification involves, I think, fundamentally two...

OncLive

 •  December 17, 2015

The total cost of care for CINV increases if there is a lot of breakthrough nausea and vomiting, which may lead to the need for intravenous fluids and/or additional antiemetics. One of the best ways to reduce overall costs is to prevent CINV from ever ...

OncLive

 •  August 18, 2015

The FDA has approved the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma at risk of relapse or progression, based on the phase III AETHERA trial.
In the study, treatment with the anti-CD30 ADC reduced the risk of disease ...

OncLive

 •  July 17, 2015

In the Ph-negative setting, the FDA approval was based on findings from a phase II study in which blinatumomab demonstrated a CR rate of 32.4% for a median duration of 6.7 months, according to the FDA. Additionally, the rate of CR/CRh was 41.6%. Overall, 80% of patients who achieved a CR also responded by MRD testing and approximately 39% of ...

OncLive

 •  July 14, 2015

A new drug application has been submitted for the oral proteasome inhibitor ixazomib (MLN9708) in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma, according to a statement from the drug's developer, Takeda. The FDA is scheduled to review the application within 60 days, at ...

OncLive

 •  April 21, 2015

The FDA has granted a priority review to the antibody-drug conjugate brentuximab vedotin (Adcetris) as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients with Hodgkin's lymphoma at risk of relapse or progression, based on findings from the phase III AETHERA trial. The FDA is scheduled to review the drug by ...